An Automated Approach To Solving Pharma’s Cardiac Toxicity Conundrum By Dr Walter Westerink, Dr Nuria Piñeiro Costas, and Beppy van de Waart The pharmaceutical industry is facing ever-growing difficulties in developing new drugs and bringing them to market (1,2). Many factors stand in the way of R&D… Read More
Chemical Space, High Throughput Screening and The World Of Blockbuster Drugs By Dr Hakim Djaballah We are constantly told that if a high throughput screen does not identify hit(s) then blame it on the compounds in your library. The community has accepted this notion and unleashed a… Read More
By Dr John Comley The majority of life sciences labs are facing an unprecedented decline in capex budgets and their subsequent ability to purchase new laboratory instruments. The default option underpinning lab instrument and equipment sales to life sciences has historically been the outright purchase… Read More
Carbon-14 Labelled API Manufacturing By Dr Sean L. Kitson and Dr David Speed Carbon-14 labelled API and IMP requirements for Phase 0/I to Phase III mass balance and micro-dosing clinical trials can be met by contract manufacturing in compliance with MHRA and FDA Phase I cGMP guidelines. Read More
Diverging Paths, Difficult Choices – Challenges Facing Pharma By Dr Steve Arlington and Dr Nick Davies Pharma is poised on a knife-edge. Major scientific and technological advances, together with socio-demographic changes, rising demand for medicines and trade liberalisation, will revive its fortunes in another decade. But in the… Read More
Biological Expression Language (BEL): Ringing In A Common Language For The Life Sciences By Ted Slater and Dr Diane H. Song Established fields of study preserve their history and support advancement by developing and using a common language, without which those fields could not progress at a reasonable… Read More
Epigenetics: Are We Hitting The Mark? By Dr Andrew J. Pope and Dr Amy M. Quinn During the last few years, advances in the understanding of epigenetic processes have led to an explosion in interest in this area as a potential source of new targets for the discovery… Read More
Enzyme-linked Immunosorbent Assays (ELISA): Recent Innovations Take Analyte Detection To New Levels By Dr John Comley Enzyme-linked immunosorbent assays (ELISA) have been around as one of the primary methods of analyte detection for more than four decades. Over the years many changes to the basic format have… Read More
The Challenges Of The Changing Drug Discovery Model By Dr Mark Downs and Dr Tom Blackburn The drug development industry is restructuring worldwide. This brings different ways of working and new challenges. As the industry moves away from internally focused research to an external model, project management… Read More
Asian Innovation: A Unique Opportunity For The Pharmaceutical Industry By Dr Yi Gu and William Shi As the third-largest market for the pharmaceutical industry, the China/Asia region is becoming increasingly important. The AstraZeneca Innovation Center China (ICC) in Shanghai is perfectly positioned to benefit from close proximity to… Read More
Editing the Human Genome: Role in Functional Genomics and Translational Medicine By Dr Chris Torrance and Eric Rhodes It is now readily accepted that we are in a post genomic era. With the steady flow of genomic information available to researchers worldwide, the focus turns to ways… Read More
New Tools Increase Accessibility to High Content Screening Assays By Dr John Comley There have been major improvements in the instrument offerings and tools that enable high content screening (HCS) over the past decade. In this review we examine the status of high… Read More
Innovate While Derisking Drug Development: Yes We Can! Taher Abbasi, Pradeep Fernandes, Dr Shireen Vali and Professor Gurkirpal Singh The outlook for the drug industry continues to remain bleak in context of productivity and success rates. In spite of ongoing increase in R&D expenses and technology revolutions in… Read More
The Information Symphony: Data orchestration for a changing industry managing data on a platform for innovation. By Chris Molloy A leading ballet conductor (1) recently told me of courses which he runs for senior business leaders. He allows them to conduct an orchestra: first, very strictly, with close… Read More
Pathway Analysis – Understanding the bridge between environmental cues and cellular response By Dr John Comley Understanding the function of a protein in the context of normal and abnormal cellular processes requires a comprehensive knowledge not only of its regulation but also of its role in signalling and… Read More
Current and Emerging Trends In Immunogenicity Research In November 2011 Drug Discovery World hosted a collegial style roundtable discussion on the present and emerging developments in this fundamental area of drug discovery and development. The participants are drawn from the biopharmaceutical, biotechnology and vendor community. Although somewhat… Read More
